Google
English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: Education
Scientific literature and patient education texts
Amyloid Cardiomyopathy
source: Herz
year: 2020
authors: Arnt V. Kristen
summary/abstract:Cardiac amyloidosis is a heterogeneous group of diseases characterized by extracellular deposition of amyloid fibrils in many different organs finally resulting in organ failure. Cardiac involvement is common for immunoglobulin light chain amyloidosis (AL) or transthyretin amyloidosis (ATTR); the latter is caused by a transthyretin gene variant or wild-type protein. Precise diagnostic assessment including laboratory tests, electrocardiography, echocardiography, cardiac magnetic resonance imaging, biopsy, and/or bone scintigraphy is mandatory for definition of the amyloid type and finally for treatment initiation.
Treatment of cardiac amyloidosis includes symptomatic therapy of heart failure as well as the underlying disease. Causative treatment of AL amyloidosis is according to regimens used for multiple myeloma. For many years, orthotopic liver transplantation was the only treatment available for hereditary ATTR amyloidosis, but important advances have been made after approval of a novel class of medication, namely, RNA silencers. However, currently no treatment is available to remove amyloid deposited in the tissue. Thus, early diagnosis is still critical to afford the best efficacy of available therapies.
DOI: 10.1007/s00059-020-04904-4
read more full text
myBinderRelated Content
-
Transthyretin Glu54Leu – An Unknown Mutation Within the Swedish Population Associated With Amyloid Cardiomyopa...For the first time, we report of a Swedi...
-
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: a plain language summaryWhat is this plain language summary abou...
-
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid CardiomyopathyBackground: Tafamidis is approved in ma...
-
US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid CardiomyopathyPfizer Inc. announced today that the US ...
-
Treatment for ATTR Cardiomyopathy – ASG Webinar 2/7https://www.youtube.com/watch?v=IzC_yaqs...
-
Pathophysiology and Treatment of Cardiac AmyloidosisAmyloid cardiomyopathy should be suspect...
-
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CMThe 30-month results of the phase 3 ATTR...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
